phaidra.vetmeduni.ac.at o:2951 DOI 10.2147/OARRR.S436637 JAK-Inhibitors - A Story of Success and Adverse Events Rheumatoid arthritis (RA) is a systemic, chronic, immune-mediated inflammatory condition. Treatments options encompass conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic disease-modifying antirheumatic drugs (bDMARDs) like tumor necrosis factor (TNF) inhibitors (TNFis) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) including Janus Kinase inhibitors (JAKinibs). Orally administered JAKinibs have demonstrated comparable or, in specific cases, superior efficacy compared to bDMARDs in inflammatory conditions. However, the escalating clinical utilization has been accompanied by the emergence of serious adverse effects, including major adverse cardiac events (MACE), malignancies and venous thrombotic episodes (VTE), leading to regulatory restrictions imposed by health authorities in both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). eng Protein-Tyrosine Kinase; Rheumatoid-Arthritis; Interferon-Alpha/Beta; Cardiovascular Events; Psoriatic-Arthritis; Cancer-Risk; Tofacitinib; Metaanalysis; Mortality; Inflammation 2024-05-07T13:19:35.501Z LOMv1.0 Author BEGIN:VCARD VERSION:3.0 N:Wlassits;Rebekka; FN:Rebekka Wlassits END:VCARD BEGIN:VCARD VERSION:3.0 N:Müller;Mathias; FN:Mathias Müller X-ORCID:https://orcid.org/0000-0002-7879-3552 END:VCARD BEGIN:VCARD VERSION:3.0 N:Fenzl;Karl H.; FN:Karl H. Fenzl END:VCARD BEGIN:VCARD VERSION:3.0 N:Lamprecht;Thomas; FN:Thomas Lamprecht END:VCARD BEGIN:VCARD VERSION:3.0 N:Erlacher;Ludwig; FN:Ludwig Erlacher END:VCARD https://w3id.org/kim/hcrt/scheme https://w3id.org/kim/hcrt/text Textdokument Text LOMv1.0 yes https://creativecommons.org/licenses/by-nc/4.0 application/pdf 440813 https://phaidra.vetmeduni.ac.at/o:2951 https://phaidra.vetmeduni.ac.at/api/object/o:2951/thumbnail LOMv1.0 discipline